Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

paclitaxel

- PMLiVE

Eli Lilly exercises option to progress autoimmune and inflammatory disease therapy

The move triggers an undisclosed milestone payment to Lilly’s partner Sitryx Therapeutics

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

More than 90% of patients with locally advanced disease are not eligible for surgery

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

- PMLiVE

Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits

Lilly is the only FDA-approved company to legally sell products containing tirzepatide

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

EU flag

EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia

Inaqovi is the first oral hypomethylating agent approved for this patient population

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

Biomarin

BioMarin announces first patient dosed with haemophilia A gene therapy in Europe

The therapy was granted conditional marketing authorisation by the EC in August 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links